Datopotamab Deruxtecan Shows Median Overall Survival Of 14.6 Months In TROPION-Lung01 Phase III Trial For Advanced Nonsquamous NSCLC; Results To Be Presented At 2024 World Conference On Lung Cancer
Author: Benzinga Newsdesk | September 09, 2024 01:51pm